Cost-effectiveness of FDG-PET

Oncologic Patients Clinical Trial

Official title:

Estudo de Custo-efetividade Para o Sistema único de Saúde - SUS Sobre o Exame de Metabolismo de Glicose Marcada Com Flúor-18 Pela Tomografia de emissão de pósitron-PET

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01438164
• Other study ID #: USP0460/05
• Status: Completed
• Phase: N/A
• First received: September 20, 2011
• Last updated: September 20, 2011
• Start date: June 2005
• Est. completion date: September 2011

Study information

• Verified date: September 2011
• Source: University of Sao Paulo
• Contact: n/a
• Is FDA regulated: No
• Health authority: Brazil: Ethics Committee
• Study type: Observational

Clinical Trial Summary

Evaluation of cost-effectiveness of FDG-PET for the public health system in Brazil.

Description:

To provide detailed information about cost and effectiveness of FDG-PET in multiple oncological diseases, such as Lymphoma, lung cancer and esophageal cancer.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 500
• Est. completion date: September 2011
• Est. primary completion date: June 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 13 Years and older

Eligibility

Inclusion Criteria:

• Cancer

Exclusion Criteria:

• Other malignancy

• Uncontrolled Diabetes

• Pregnancy

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Oncologic Patients

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
University of Sao Paulo	Netherlands: Ministry of Health, Welfare and Sports